Metagenomi

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world.

The company was founded in 2018 and is headquartered in Emeryville, California.

Metagenomi headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Therapeutics sector. The company focuses on Biotechnology and has secured $51.2B in funding across 112 round(s). With a team of 101-250 employees, Metagenomi is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Metagenomi, raised $100.0M. Discover more about their projects, partnerships, and impact on our platform.